Substantial Variability in Pediatric MOGAD Treatment Decisions, Timing of Treatment Identified

A recent survey revealed significant variability in treatment decisions for pediatric MOGAD, highlighting gaps in knowledge and the potential need for improved clinical guidelines.:

Source: Neurology Read More

Previous PostInternational Case Series Reveals Meningitis as a Potential Underrecognized Feature of MOGAD
Next PostOverviewing the Clinical use of the CARM Score in Alzheimer Disease Detection: James Galvin, MD

Substantial Variability in Pediatric MOGAD Treatment Decisions, Timing of Treatment Identified

Previous PostInternational Case Series Reveals Meningitis as a Potential Underrecognized Feature of MOGAD

Next PostOverviewing the Clinical use of the CARM Score in Alzheimer Disease Detection: James Galvin, MD

Related Posts

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

<![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

Categories